Relapsed Or Refractory Light-Chain (AL) Amyloidosis
AUTLAutolus TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for AUTO8 (BCMA & CD19) (BCMA CD19 CAR-T) in Relapsed Or Refractory Light-Chain (AL) Amyloidosis. The expected timing is based on the latest available company guidance and may change.
12/01/25:- Phase 1 ALARIC study of AUTO8 in relapsed or refractory AL amyloidosis is expected to dose its first patient by year-end 2025. 03/27/26:- ALARIC Phase 1 AUTO8 AL amyloidosis trial dosed first patient; initial data expected by year-end 2026. 08/11/26:- ALARIC Phase 1 initial data remains expected by YE 2026.
Verification
Confirm timing and program details against the company announcement or filing.